TY - JOUR
T1 - Endometrial endometrioid carcinoma, grade 1, is more aggressive in the elderly than in the young
AU - Hachisuga, Kazuhisa
AU - Ohishi, Yoshihiro
AU - Tomonobe, Hiroshi
AU - Yahata, Hideaki
AU - Kato, Kiyoko
AU - Oda, Yoshinao
N1 - Funding Information:
We would like to thank all of the technical staff of the Department of Pathology, Kyushu University for their assistance. We thank Professor Mototsugu Shimokawa from the department of biostatistics, Yamaguchi University, for helping with statistical analyses. We also appreciate the technical assistance from the Research Support Centre, Kyushu University Graduate School of Medical Sciences. This research was supported by a grants-in-aid from the ‘FUKUOKA’ OBGYN Researcher’s Charity Foundation Fund, Japan.
Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021/11
Y1 - 2021/11
N2 - Aims: The aim of this study was to characterise grade 1 (G1) endometrioid carcinoma in the elderly, by using clinicopathological features and immunohistochemical features of surrogate markers of molecular subtypes. Methods and results: We retrospectively analysed tumour samples from 268 patients with G1 endometrioid carcinoma (<40 years, n = 24; 40–59 years, n = 169; ≥60 years, n = 75) for whom long-term clinical follow-up data were available. G1 endometrioid carcinoma in the elderly (≥60 years) was characterised by frequent deep myometrial invasion, less frequent endometrioid intraepithelial neoplasia (EIN), lack of benign hyperplasia (BH), less frequent squamous differentiation, and occasional aberrant p53 expression. In contrast, this condition in the young (<40 years) was characterised by frequent EIN, BH, and squamous differentiation. Univariate analysis revealed that elderly status (≥60 years), International Federation of Obstetrics and Gynecology (FIGO) 2009 stage and aberrant p53 expression were significantly associated with shorter progression-free survival, and multivariate analysis revealed that elderly status and FIGO 2009 stage were independently associated with a poor prognosis. Conclusions: G1 endometrioid carcinoma in the elderly is more aggressive than that in the young, and elderly status is an independent predictor of shorter progression-free survival in this condition. We propose that type 1 tumours can be subdivided into type 1a (young age at onset and indolent) and type 1b (old age at onset and relatively aggressive).
AB - Aims: The aim of this study was to characterise grade 1 (G1) endometrioid carcinoma in the elderly, by using clinicopathological features and immunohistochemical features of surrogate markers of molecular subtypes. Methods and results: We retrospectively analysed tumour samples from 268 patients with G1 endometrioid carcinoma (<40 years, n = 24; 40–59 years, n = 169; ≥60 years, n = 75) for whom long-term clinical follow-up data were available. G1 endometrioid carcinoma in the elderly (≥60 years) was characterised by frequent deep myometrial invasion, less frequent endometrioid intraepithelial neoplasia (EIN), lack of benign hyperplasia (BH), less frequent squamous differentiation, and occasional aberrant p53 expression. In contrast, this condition in the young (<40 years) was characterised by frequent EIN, BH, and squamous differentiation. Univariate analysis revealed that elderly status (≥60 years), International Federation of Obstetrics and Gynecology (FIGO) 2009 stage and aberrant p53 expression were significantly associated with shorter progression-free survival, and multivariate analysis revealed that elderly status and FIGO 2009 stage were independently associated with a poor prognosis. Conclusions: G1 endometrioid carcinoma in the elderly is more aggressive than that in the young, and elderly status is an independent predictor of shorter progression-free survival in this condition. We propose that type 1 tumours can be subdivided into type 1a (young age at onset and indolent) and type 1b (old age at onset and relatively aggressive).
UR - http://www.scopus.com/inward/record.url?scp=85109371033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109371033&partnerID=8YFLogxK
U2 - 10.1111/his.14400
DO - 10.1111/his.14400
M3 - Article
C2 - 33982792
AN - SCOPUS:85109371033
SN - 0309-0167
VL - 79
SP - 708
EP - 719
JO - Histopathology
JF - Histopathology
IS - 5
ER -